Earnings ·
Neurogene Inc. reported second quarter 2026 financial results on August 11, 2026, announcing a net loss of $34.5…
NGNENeurogene Inc.
Neurogene Inc. reported second quarter 2026 financial results on August 11, 2026, announcing a net loss of $34.5 million compared to $22.0 million in the prior year period. The company completed dosing of all 25 participants in its Embolden registrational trial for NGN-401 and initiated Process Performance Qualification runs expected by year-end 2026. Long-term Phase 1/2 data showed 100% of participants improved on the CGI-I scale, gaining an average of 4.7 developmental milestones with no plateau observed through 30 months. Neurogene also executed an oversubscribed public offering generating approximately $144 million in gross proceeds, extending its cash runway into the first quarter of 2029. The company operates as a clinical-stage biotechnology firm developing genetic medicines for rare neurological diseases.